MicroSEQ E. coli O157:H7 Detection Assay Also Receives Industry Validation from AOAC Research Institute

CARLSBAD, Calif. – Life Technologies (NASDAQ:LIFE), a provider of innovative life science solutions, announced at the International Association of Food Protection annual meeting the launch of the MicroSEQ(R) E. coli O157:H7 assay, designed to detect the deadly strain of Escherichia coli (E. coli), using the company’s industry-leading real-time PCR technology. Life Technologies also announced that the assay has secured Performance Tested MethodsSM certification from the AOAC Research Institute for detection of E. coli O157:H7. The new product will enable more effective monitoring of the food supply for contamination and help ensure food safety.

E. coli O157:H7 can cause severe illness, even death and has been responsible for significant outbreaks of food poisoning across the globe. Culture-based assays, long considered the gold standard for pathogen detection, can take up to five days to yield results. The MicroSEQ E. coli O157:H7 detection assay is highly specific and sensitive and can be run in as little as eight hours.

“Food companies and food testing organizations are seeking validated tools to help safeguard the public from organisms such as E. coli O157:H7,” said Dr. Sharon Brunelle, technical consultant, AOAC Research Institute. “Life Technologies has demonstrated that the MicroSEQ E. coli O157:H7 Detection Kit performs as well or better than the ISO and USDA reference methods for a variety of foods, earning Performance Tested Methods certification from the AOAC Research Institute.”

The AOAC Research Institute focuses on the development, use, and harmonization of validated analytical methods and its validation is important for food safety. The certification of the MicroSEQ E. coli O157:H7 detection assay means that the assay meets the stringent pathogen detection requirements of many companies and testing organizations responsible for safeguarding food supplies.

“Food contamination is a serious issue, one that can unfortunately have life-threatening repercussions,” said Brian Kim, general manager responsible for food protection solutions at Life Technologies. “With the introduction of the MicroSEQ E. coli O157:H7 assay, Life Technologies is adding to the arsenal of tools available to authorities to help ensure a safe and reliable global food supply.”

The assay is part of a growing portfolio of MicroSEQ kits designed to detect pathogens that contaminate the food supply, including the MicroSEQ Salmonella spp. Detection Kit, the MicroSEQ Listeria monocytogenes Detection Kit and the MicroSEQ Listeria spp Detection Kit.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: https://www.lifetechnologies.com.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

SOURCE: Life Technologies